U.S. Logistics Stock News

NYSE:P
NYSE:PTech

Everpure (P) Draws Jana Partners Stake Ahead Of Public Filing

Jana Partners has built a significant new position in Everpure, NYSE:P. The holding is set for imminent regulatory disclosure, shifting it from confidential to public information. This marks the first public indication of activist interest in Everpure from Jana Partners. Everpure, NYSE:P, now sits in the spotlight as investors weigh what an activist stake from Jana Partners could mean for the company. Everpure operates in an environment where management decisions, capital allocation and...
NasdaqGS:QCOM
NasdaqGS:QCOMSemiconductor

Has QUALCOMM (QCOM) Become Fully Priced As It Exits Russell Growth Indexes?

QUALCOMM dropped from multiple Russell growth and defensive indexes QUALCOMM (QCOM) has been removed from several Russell growth and defensive benchmarks, a technical reshuffle that can affect how index funds and quantitative investors treat the stock in the short term. These deletions include exits from growth focused and defensive oriented versions of the Russell 1000 and Russell 3000 families, as well as the Russell Top 200 Growth Benchmark. For index trackers and rules based mandates,...
NasdaqGS:DDOG
NasdaqGS:DDOGSoftware

Is Datadog (DDOG) Expensive After Its Adaptive ML Acquisition?

Datadog stock reacts to AI-focused acquisition Datadog (DDOG) drew fresh investor attention after announcing the acquisition of frontier AI startup Adaptive ML, a move aimed at strengthening its AI research capabilities for observability and security products. See our latest analysis for Datadog. Recent AI focused headlines have come on top of strong momentum in Datadog’s share price, with a 7 day share price return of 18.79% and a 90 day share price return of 119.74%. The 1 year total...
NYSE:BA
NYSE:BAAerospace & Defense

Boeing (BA) Stock Looks Below Fair Value Despite Cash Flow Risks

Boeing stock sits in an unusual valuation spot right now, with the Discounted Cash Flow (DCF) estimate pointing to sizeable upside relative to the current price, while market multiples lean the other way and recent five year returns have been slightly negative. Over the past 5 years, Boeing has declined about 5.7%, which suggests the share price has not kept pace with the company’s shifting business mix and investor expectations. New long term defense and space work, such as the MUOS...
NasdaqGS:LULU
NasdaqGS:LULULuxury

Lululemon (LULU) Faces Consumer Lawsuit Over Tariff Price Increases

Consumer-protection lawsuit filed against lululemon athletica alleging improper retention of tariff-linked price increases. Case claims the company has pursued recovery of now-invalidated tariffs without committing to refund affected customers. Legal action raises questions about consumer treatment, potential financial liability, and brand impact for NasdaqGS:LULU. Lululemon athletica, traded on NasdaqGS:LULU, is facing fresh legal scrutiny that lands at a sensitive time for the stock...
NasdaqGS:PATK
NasdaqGS:PATKAuto Components

Patrick Industries (PATK) Merger Call Puts Its Undervalued Narrative To The Test

Merger call puts Patrick Industries in focus Patrick Industries (PATK) is drawing fresh attention after scheduling a call to discuss a definitive agreement for an all stock merger with LCI Industries. This potential combination could significantly influence the company’s future footprint. See our latest analysis for Patrick Industries. Alongside the merger announcement and recent additions to several Russell value indices, Patrick Industries’ share price has slipped 3.65% over the past day...
NYSE:CXW
NYSE:CXWCommercial Services

How CoreCivic’s Shift Into Value‑Defensive Indices Will Impact CoreCivic (CXW) Investors

On 27 June 2026, CoreCivic, Inc. was removed from several Russell growth benchmarks and simultaneously added to the Russell 2000 Value-Defensive and Russell 2000 Defensive indices, marking a formal shift in how index providers classify the stock. This reclassification highlights a move away from a growth profile toward a more defensive and value-oriented perception, which may gradually reshape CoreCivic’s investor base and how its risk‑return characteristics are viewed. We’ll now examine how...
NYSE:UHAL
NYSE:UHALTransportation

What U-Haul Holding (UHAL)'s Removal From Russell 1000 Defensive Indices Means For Shareholders

In late June 2026, U-Haul Holding Company was removed from several Russell 1000 classifications, including the Growth-Defensive, Defensive, and Value-Defensive indices for both its UHAL and UHAL.B share classes. This broad index exclusion highlights how U-Haul’s investment profile is now being reassessed by index providers, which can influence how passive and quantitative investors view the stock. With U-Haul’s removal from multiple Russell 1000 defensive-style indices, we’ll examine how...
NYSE:OKLO
NYSE:OKLOElectric Utilities

Oklo (OKLO) Wins DOE Safety Approval For Groves Isotope Test Reactor

U.S. Department of Energy approves the final Documented Safety Analysis for Oklo's Groves Isotope Test Reactor. The reactor now moves into the last pre-startup review phase ahead of potential first criticality. Approval positions Oklo to pursue domestic commercial production of critical medical and industrial isotopes. For investors watching NYSE:OKLO, this regulatory sign off arrives while the stock trades at $52.33 and has had mixed recent returns. The share price is down 8.5% over the...
NasdaqCM:EOSE
NasdaqCM:EOSEElectrical

Eos Energy (EOSE) Secures $225 Million To Back Frontier Power USA Plans

Eos Energy Enterprises (NasdaqCM:EOSE) agreed to a $75 million direct offering and a $150 million rights distribution tied to its Frontier Power USA joint venture. The financing package is designed to support long duration energy storage projects and a project pipeline linked to more than $1.5b in potential financing. New institutional partners are providing direct equity commitments that reshape the company's capital structure and funding options. Eos Energy Enterprises comes into this...
NYSE:DLR
NYSE:DLRSpecialized REITs

Digital Realty Trust (DLR) Sells New Equity, Is The Pullback A Buying Opportunity?

Digital Realty Trust (DLR) just completed a US$2.28b follow on equity offering of common stock, a financing move that gives investors fresh information on capital allocation and potential dilution at the current share price. See our latest analysis for Digital Realty Trust. Digital Realty Trust shares have come under pressure around the follow on equity offering and recent Northern Virginia and Kansas City data center deals, with the share price down 5.8% on the day and 7.9% over the past...
NYSE:SBSI
NYSE:SBSIBanks

Is Southside Bancshares (SBSI) Below Fair Value On Its Russell Index Additions?

Index additions put Southside Bancshares in front of more investors Southside Bancshares (SBSI) has been added to several Russell growth and small cap benchmarks, a move that can draw extra attention from index-tracking funds and reshape how investors look at the stock. See our latest analysis for Southside Bancshares. The index inclusions come after a period of building momentum for Southside Bancshares, with a 30 day share price return of 7.42% and year to date share price return of 15.57%...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

Expedia (EXPE) Stock Looks Cheap On Earnings But Pricey After 130% Run

Expedia Group stock has delivered a strong 129.7% return over the past three years, so the current question is whether that performance is still backed up by what the valuation checks are saying or whether expectations are starting to run ahead of the fundamentals. Over three years, Expedia Group has returned 129.7%, which puts added weight on whether today’s price still offers enough compensation for risk. Recent research on fully connected hotels and an expanded platform that can benefit...
NYSE:BMY
NYSE:BMYPharmaceuticals

Bristol Myers Squibb (BMY) Joins Defensive Value Indexes, Is It Still 8% Undervalued?

Bristol-Myers Squibb (BMY) is being reclassified across key Russell indexes, exiting several growth benchmarks and entering the Russell 1000 Defensive and Russell 1000 Value Defensive Indexes, a shift that can influence passive fund positioning. See our latest analysis for Bristol-Myers Squibb. At a share price of US$57.62, Bristol-Myers Squibb has a year to date share price return of 7.78%, while its 1 year total shareholder return of 27.34% contrasts with a 6.66% decline over 90 days. This...
NYSE:RMD
NYSE:RMDMedical Equipment

ResMed (RMD) Stock Looks Reasonable After A 23% Fall

ResMed stock has fallen 23.2% over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiples currently point to the shares trading at a discount to what the business may be worth. Over the last 12 months the share price declined 23.2%, which means the market has already reset expectations even as valuation indicators lean supportive. Recent coverage has highlighted recurring revenue from sleep apnea devices and software as a potential support...
NYSE:F
NYSE:FAuto

Ford (F) Stock Still Looks Undervalued Following Its 29% Five Year Gain

Ford Motor stock has delivered a 29.3% return over the past five years, and the latest checks suggest the market price may still sit below what both an intrinsic value estimate and market multiples imply. Over the past 5 years, Ford Motor shares have returned 29.3%, pointing to a steady, if unspectacular, payoff for long term holders. Progress on lower cost LFP batteries and energy storage can support expectations for future cash flows, while recurring recalls and product quality issues...
NasdaqGS:ADSK
NasdaqGS:ADSKSoftware

Is Autodesk (ADSK) A Bargain On Russell Changes And Its $350 Million AI Push?

Autodesk (ADSK) has just been reshuffled across several Russell indices, including additions to the Russell Midcap Growth and Russell 1000 Defensive indices, while also announcing a US$350 million commitment to global AI-focused education. See our latest analysis for Autodesk. At a share price of US$194.42, Autodesk has seen its 7 day share price return rise 2.99%. However, the 30 day and year to date share price returns are down 15.95% and 32.19% respectively, while the 1 year total...
NYSE:PWR
NYSE:PWRConstruction

Quanta Services (PWR) Stock Could Trade At A Premium Following Raised Outlook

Quanta Services has delivered a very large 5 year gain of about 7x, yet the stock now screens as expensive, with a low value score and market multiples pointing to an overvalued profile despite the strong operational story around power and AI related infrastructure. Over the last 5 years, Quanta Services has returned roughly 725%, which puts extra focus on whether the current share price already reflects much of the good news. Expectations for continued demand tied to grid modernization and...
NasdaqGS:RKLB
NasdaqGS:RKLBAerospace & Defense

Rocket Lab (RKLB) Stock May Be Fully Priced On Cash Flow And Broader Checks

Rocket Lab stock has delivered a very large 3 year gain, yet the valuation checks now point to a richer pricing, with both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples indicating the shares trade at a premium rather than a clear bargain. Over the past 3 years, Rocket Lab has returned about 16x, which sets a high bar for any further upside to be justified by future cash flows. The planned acquisition of Iridium Communications and expansion into vertically...
NasdaqCM:EVLV
NasdaqCM:EVLVElectronic

Evolv Technologies Holdings (EVLV) Renews TD Garden Deal, Is The Stock Cheap?

Evolv Technologies Holdings (EVLV) drew fresh investor attention after announcing a multi-year renewal and upgrade of its hardware and software subscription agreement with TD Garden, reinforcing its role in the arena’s security screening operations. See our latest analysis for Evolv Technologies Holdings. At a share price of $5.80, Evolv Technologies Holdings has seen a 1-day share price return of 3.39% and a 7-day share price return of 4.69%. The 30-day share price return is down 10.08% and...
NasdaqCM:MAMA
NasdaqCM:MAMAFood

India Monsoon Shock Puts Global Food Exporter Stocks In Focus

India’s driest June in 12 years, with rainfall nearly 40% below forecast and sharp drops in rice and oilseed sowing, is reshaping expectations for global agriculture and food trade. When a major buyer like India faces weaker crop output, attention often shifts to exporters that can step in to meet demand for staples such as rice, edible oils, pulses, and grains. This article examines how that shock filters through to large listed agriculture and food exporters and highlights 3 stocks from our...
NasdaqGS:SNEX
NasdaqGS:SNEXCapital Markets

Does StoneX Group’s (SNEX) Bank Research Push Reveal a Deeper Capital Markets Strategy Shift?

In late June 2026, StoneX Group Inc. (NasdaqGS: SNEX) was added to the Russell 2000 Dynamic Index and expanded its capital markets offering by launching a Financial Institutions Group research practice via subsidiary The Benchmark Company, focused on regional and community banks. This combination of index inclusion and new bank-focused research deepens StoneX’s role in the regional banking ecosystem and broadens its fee-generating service capabilities. Next, we’ll examine how the new...
NasdaqGS:PPC
NasdaqGS:PPCFood

Pilgrim's Pride (PPC) Faces Weaker Earnings Views, Is It Still A Bargain?

Fresh attention on Pilgrim's Pride (PPC) follows recent analyst coverage citing weaker earnings estimates and a lower rating, while revenue figures have shown some improvement and sentiment remains cautious. See our latest analysis for Pilgrim's Pride. At a share price of $28.11, Pilgrim's Pride has seen short term share price pressure, including a 1 day share price return that declined 2.9%, while the 3 year total shareholder return of 53.2% and 5 year total shareholder return of 51.72% show...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

How Teva’s Ecopipam NDA for Pediatric Tourette Syndrome (TEVA) Has Changed Its Investment Story

In June 2026, Teva Pharmaceutical Industries announced it had submitted a New Drug Application to the FDA for ecopipam, a first-in-class dopamine D1 receptor antagonist for pediatric Tourette syndrome, supported by positive Phase 3 data published in JAMA Neurology and Orphan Drug and Fast Track designations. The filing positions Teva to potentially introduce the first new FDA-approved pediatric Tourette syndrome treatment in more than a decade, extending its focus on neurology and rare...